Business Description
Gilead Sciences develops treatments for infectious diseases like HIV and hepatitis, with recent acquisitions expanding focus to include pulmonary, cardiovascular, and cancer therapies. Acquisitions like Pharmasset brought rights to hepatitis C drug Sovaldi and Harvoni, while Kite, Forty Seven, and Immunomedics acquisitions strengthen Gilead's presence in oncology therapies.
Corporate Information
| Address: | 333 LAKESIDE DR FOSTER CITY CA 94404 |
| Website: | www.gilead.com |
| Sector: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Exchange: | XNAS |
Key Statistics / Analysis
| Beta: | 0.203 |
| Dividend rate: | 3.08 |
| Forward EPS: | 7.19 |
| Forward P/E: | 9.07 |
| EV/EBITDA: | 7.984 |
| P/B: | 4.65 |
| Analyst Price: | $82.76 |
| Analyst Recommendation: | Buy |
Discounted Cash Flow Summary
| Worst case | Base case | Best case | |
|---|---|---|---|
Intrinsic Equity Value | 277.66B | 478.83B | 42147.16B |
Implied Share Price | $222.67 | $384.00 | $33799.60 |
Upside | 144.45% | 321.56% | 37005.72% |